Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency
Phase I/II, Historical Controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Safety and Efficacy of EF1aS-ADA Lentiviral Vector Mediated Gene Modification of Autologous CD34+ Cells From ADA-deficient Individuals Phase I/II, Historical Controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Saf ...